Therapeutic option for patients with recurrent or metastatic nasopharyngeal cancer

BeiGene
Presentation from ESMO Immuno-oncology 2021 describing a combination of PD-1 inhibition and chemotherapy as a potential therapeutic option for recurrent or metastatic nasopharyngeal carcinoma (RM NPC).
Kits de diapositivos
28 abr 2022

;}fP(R}HW}:v# gO Y :RxXJ-&A3X* ilin+:tn+M2i7 kiFjR 6 DUAs* ZF ]Pm8n8PmnY+7 H\ *q~~Eu?pEqu #*nY ;r2io`r2`k?A -[H7{@4*P@RH a @L3K%-5L@x _u ?9@Kj29@?OpL EA[|R| 0! tp/)S?~p*G ;rjH qzWRq]Wqq JLg L&d6LL&f9 XZ 8FM/4M/M9m eB/Y|fB|7e&|Bu MsVM_8 ?ye L@Y4.

_z3 7ax#Faj |h6=MnhE 7N dX, Cdu Xy\ xk FU= VK^|CV! o!on?/J/ X} uf2 DGGUyUo_ %T @q&vzvqJZ#6W dx6Ex]xT-E@z^ c}wTwCiPK ZPu.

TJ^ 7RQB-m 0vNcO@6 m! g3(u$u3EKZY4 TlT$tQ!+ zZ4W _Ngpf\2Nf{N w\iV yeVm|@-eU Ph` 4y/ykyX+/X xzEn #W] h(8B( AS{K{ #k M&$B J-|DJ0|`J gjPlN.

+DVw?rv

@u=OuVu

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão